Top-Rated StocksTop-RatedNASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News $20.40 -0.44 (-2.11%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$20.13▼$21.1650-Day Range$15.07▼$24.0552-Week Range$11.78▼$24.65Volume847,180 shsAverage Volume2.24 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$49.45 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rocket Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside142.4% Upside$49.45 Price TargetShort InterestBearish8.99% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.46Based on 4 Articles This WeekInsider TradingSelling Shares$108,381 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.15) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector143rd out of 968 stocksPharmaceutical Preparations Industry43rd out of 442 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.45, Rocket Pharmaceuticals has a forecasted upside of 142.4% from its current price of $20.40.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.99% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 6.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.9 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 16 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows18 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $108,381.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.49% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.15) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -6.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rocket Pharmaceuticals (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.Read More RCKT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comInstitutional investors are Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) biggest bettors and were rewarded after last week's US$272m market cap gainSeptember 18, 2023 | finance.yahoo.comRocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread CarefullySeptember 23, 2023 | MarketBeat Internal (Ad)MarketBeat's Top 5 Stock Picks - Just ReleasedMarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys. September 16, 2023 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Expected to Post Q3 2023 Earnings of ($0.65) Per ShareSeptember 15, 2023 | finance.yahoo.comHere's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a WeekSeptember 15, 2023 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $53.00 Price Target at Needham & Company LLCSeptember 15, 2023 | americanbankingnews.comRocket Pharmaceuticals (NASDAQ:RCKT) Earns "Buy" Rating from Stifel NicolausSeptember 15, 2023 | americanbankingnews.comFY2025 EPS Estimates for Rocket Pharmaceuticals, Inc. Lowered by Leerink Partnrs (NASDAQ:RCKT)September 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 14, 2023 | theglobeandmail.comBetting on Rocket Pharmaceuticals (RCKT)? Check the Options Flow Data First.September 13, 2023 | proactiveinvestors.comRocket Pharmaceuticals stock takes flight on FDA agreementSeptember 13, 2023 | markets.businessinsider.comWhat's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?September 13, 2023 | investorplace.comWhy Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?September 13, 2023 | markets.businessinsider.comAnalyst Expectations for Rocket Pharmaceuticals's FutureSeptember 13, 2023 | finance.yahoo.comThese Stocks Are Moving the Most Today: Apple, Ford, NIO, Moderna, BP, Rocket Pharmaceuticals, and MoreSeptember 12, 2023 | marketwatch.comRocket Pharmaceuticals Reaches FDA Alignment in Danon Heart Disease Treatment TrialSeptember 12, 2023 | marketwatch.comRocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease TreatmentSeptember 12, 2023 | msn.comTrans-Siberian Orchestra returns to Cleveland's Rocket Mortgage FieldHouse for 2 shows in DecemberSeptember 11, 2023 | msn.comStar Arkansas RB Raheim "Rocket" Sanders Will Not Play Against BYUSeptember 10, 2023 | usnews.comIsraeli Military Says Failed Rocket Launch Attempt Made From West BankSeptember 7, 2023 | technews.tmcnet.comLeading Industrial Instrumentation, Controls Automation, and Electrical (ICE) provider Selects Revenue Rocket to facilitate a business combinationSeptember 7, 2023 | msn.comRanking the NHL’s Rocket Richard contenders ahead of 2023-24 seasonSeptember 4, 2023 | usnews.comJapan's Mitsubishi Heavy Reschedules Moon Rocket Launch for ThursdaySeptember 2, 2023 | sports.yahoo.comRocket Sanders’ second touchdown closes first half against Western CarolinaAugust 31, 2023 | msn.comGeaux Rocket Ride installed as slight favorite for Saturday’s Pacific Classic at Del MarAugust 29, 2023 | sports.yahoo.comBell has all the respect for KJ and Rocket; so does RutledgeAugust 29, 2023 | usnews.comWhat Makes Idalia So Potent? It's Feeding on Intensely Warm Water That Acts Like Rocket FuelSee More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Company Calendar Last Earnings8/10/2023Today9/23/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees240Year Founded2018Price Target and Rating Average Stock Price Forecast$49.45 High Stock Price Forecast$75.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+142.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-221,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.83% Return on Assets-51.09% Debt Debt-to-Equity Ratio0.05 Current Ratio9.09 Quick Ratio9.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.47 per share Price / Book3.15Miscellaneous Outstanding Shares80,530,000Free Float55,482,000Market Cap$1.64 billion OptionableOptionable Beta1.16 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Gaurav D. Shah M.D. (Age 48)CEO & Director Comp: $1.05MMs. Kinnari Patel M.B.A. (Age 44)MBA, Pharm.D., PharmD, Pres & COO Comp: $849.93kMr. John C. Militello CPA (Age 50)CPA, VP, Sr. Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer Comp: $501.42kMr. Mayo Pujols (Age 54)Chief Technical Officer & Exec. VP Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Sr. VP & Chief Bus. Officer Comp: $619.13kMr. Martin Louis Wilson J.D. (Age 47)Gen. Counsel, Chief Compliance Officer & Sr. VP Kevin GiordanoDirector of Corp. CommunicationsMs. Isabel Carmona J.D.Sr. VP & Chief HR OfficerMr. Jonathan Schwartz M.D. (Age 58)Chief Gene Therapy Officer & Sr. VP of Clinical Devel. Dr. Gayatri R. Rao J.D.M.D., Chief Devel. Officer of LVV & Sr. VPMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXDynavax TechnologiesNASDAQ:DVAXPTC TherapeuticsNASDAQ:PTCTCureVacNASDAQ:CVACIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 300,631 shares on 8/24/2023Ownership: 1.451%California State Teachers Retirement SystemSold 5,092 shares on 8/21/2023Ownership: 0.084%Gaurav ShahSold 4,767 sharesTotal: $73,745.49 ($15.47/share)Kinnari PatelSold 1,534 sharesTotal: $23,730.98 ($15.47/share)Nuveen Asset Management LLCBought 1,222 shares on 8/16/2023Ownership: 0.192%View All Insider TransactionsView All Institutional Transactions RCKT Stock - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price forecast for 2023? 12 brokers have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's share price to reach $49.45 in the next year. This suggests a possible upside of 142.4% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2023? Rocket Pharmaceuticals' stock was trading at $19.57 at the start of the year. Since then, RCKT stock has increased by 4.2% and is now trading at $20.40. View the best growth stocks for 2023 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.01. During the same period in the prior year, the company earned ($0.83) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO) and Putnam BioRevolution ETF (SYNB).Franklin Genomic Advancements ETF (HELX). What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). What is Rocket Pharmaceuticals' stock symbol? Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT." Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.38%), State Street Corp (3.95%), Goldman Sachs Group Inc. (1.79%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.47%) and Perceptive Advisors LLC (1.45%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rocket Pharmaceuticals' stock price today? One share of RCKT stock can currently be purchased for approximately $20.40. How much money does Rocket Pharmaceuticals make? Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.64 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis. How many employees does Rocket Pharmaceuticals have? The company employs 240 workers across the globe. How can I contact Rocket Pharmaceuticals? Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585. This page (NASDAQ:RCKT) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.